Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The promotion of cellular differentiation into benign cells refers to the process by which undifferentiated or malignant (cancerous) cells are induced to become mature, specialized cell types that exhibit non-cancerous (benign) behavior. This concept is central in cancer biology and regenerative medicine, as it underlies strategies aimed at reprogramming or redirecting malignant cells toward a less aggressive, more controlled phenotype. It involves epigenetic mechanisms, cell cycle dynamics, and extrinsic factors to drive cells towards terminal differentiation, potentially suppressing proliferation and tumor aggressiveness.
Induction of differentiation pathways, epigenetic modulation, and alteration of cell cycle dynamics to promote differentiation into benign cell types and suppress malignant phenotypes.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Promotion of Cellular Differentiation into Benign Cells.